Morgan Thomas
Psychiatric/Mental Health · Deland, FLNPI 1992271134
Payments from drug & device makers
Across 161 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$962
- Otsuka America Pharmaceutical, Inc.$400
- Vanda Pharmaceuticals Inc.$378
- Supernus Pharmaceuticals, Inc.$316
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$187
- Axsome Therapeutics, Inc.$157
- plus $564 from 11 others
What the payments were for
- Food & beverage$2,93799%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,964 in reported general payments places this provider in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $106,455 |
| VraylarCariprazine Hcl | 45 | $67,219 |
| Aripiprazole | 47 | $6,055 |
| Quetiapine Fumarate | 107 | $2,308 |
| Hydroxyzine Hcl | 95 | $1,662 |
| Buspirone Hcl | 153 | $1,631 |
| Atomoxetine Hcl | 19 | $912 |
| Amitriptyline Hcl | 45 | $745 |
| Oxcarbazepine | 38 | $714 |
| Lurasidone Hcl | 23 | $651 |
| Lamotrigine | 98 | $554 |
| Mirtazapine | 56 | $482 |
| Prazosin Hcl | 55 | $413 |
| Trazodone Hcl | 43 | $409 |
| Sertraline Hcl | 76 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $41 | $106,45514 claims |
| AbbVieVraylar | $962 | $67,21945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Deland
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.